This gene is predominantly expressed in prostate tissue, and is found to be upregulated in multiple cancer cell lines. The gene product is predicted to be a six-transmembrane protein, and was shown to be a cell surface antigen significantly expressed at cell-cell junctions.
|CAT||Product Name||Target Species||Antibody Clone||Antibody Host||Epitope||HLA||Vector Type|
|TCR-C241Z||Murinized anti-STEAP1 T cell receptor (P2A5), pCDTCR1||Human||P2A5||Murinized||YLPGVIAAI||HLA-A*0201||Lentiviral|
|CAT||Product Name||Clone||Promotor||Packaging System||Targeting Diseases|
|VP-TCR-C498||Lenti-STEAP1 T cell receptor (P2A5) Viral Particle||P2A5||CMV||Lentivirus|
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell to be a promising cellular therapy with the complete TCR without HLA dependence.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE